臨床神経学

<シンポジウム(1)―2―5>免疫性末梢神経障害Update

POEMS症候群の新規治療の現状と今後の課題

三澤 園子

千葉大学大学院医学研究院神経内科学〔〒260―8670 千葉市中央区亥鼻1―8―1〕

POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome is characterized by neuropathy with multiorgan involvement. High-dose chemotherapy with auto-peripheral blood stem cell transplantation (ASCT) and thalidomide, which are new therapeutic approaches to POEMS syndrome could salvage lots of patients with POEMS syndrome and substantially improve the prognosis. However there have been not a few patients who experienced recurrence after ASCT, and part of those patients suffered very mild symptom at the time of the treatment. Indication of ASCT should be reconsidered and different therapeutic strategy such as combined thalidomide with ASCT might decrease risk of recurrence. Moreover we should consider other therapeutic option such as lenalidomide or bortezomib for refractory patients.
Full Text of this Article in Japanese PDF (167K)

(臨床神経, 52:923−924, 2012)
key words:POEMS症候群,血管内皮増殖因子,自己末梢血幹細胞移植,サリドマイド

(受付日:2012年5月23日)